Abstract
The association between the expression of vascular endothelial growth factor (VEGF) and clinicopathological factors has scarcely been examined in cervical cancer. This study examines the level of VEGF messenger RNA (mRNA) expression in invasive cervical cancer and its association with clinicopathological features including microvessel density. The level of VEGF mRNA was assessed by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) using β-actin as an internal control in 66 patients with stages Ia-IVb invasive cervical cancer. In 42 patients who underwent surgery, the microvessel count was also assessed by immunostaining for factor VIII- related antigen in the most neovascularised area of the specimen. The highest level of VEGF mRNA expression was observed in early invasive cervical cancers. Except for stage IVb, the stage of the disease inversely correlated with the level of VEGF mRNA (P
| Original language | English |
|---|---|
| Pages (from-to) | 485-489 |
| Number of pages | 5 |
| Journal | European Journal of Cancer |
| Volume | 35 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1999 |
| Externally published | Yes |
Fingerprint
Keywords
- Angiogenesis
- Cervical cancer
- Reverse transcription-polymerase chain reaction
- Vascular endothelial growth factor
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Vascular endothelial growth factor is implicated in early invasion in cervical cancer. / Kodama, J.; Seki, N.; Tokumo, K.; Hongo, A.; Miyagi, Y.; Yoshinouchi, M.; Okuda, H.; Kudo, T.
In: European Journal of Cancer, Vol. 35, No. 3, 03.1999, p. 485-489.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vascular endothelial growth factor is implicated in early invasion in cervical cancer
AU - Kodama, J.
AU - Seki, N.
AU - Tokumo, K.
AU - Hongo, A.
AU - Miyagi, Y.
AU - Yoshinouchi, M.
AU - Okuda, H.
AU - Kudo, T.
PY - 1999/3
Y1 - 1999/3
N2 - The association between the expression of vascular endothelial growth factor (VEGF) and clinicopathological factors has scarcely been examined in cervical cancer. This study examines the level of VEGF messenger RNA (mRNA) expression in invasive cervical cancer and its association with clinicopathological features including microvessel density. The level of VEGF mRNA was assessed by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) using β-actin as an internal control in 66 patients with stages Ia-IVb invasive cervical cancer. In 42 patients who underwent surgery, the microvessel count was also assessed by immunostaining for factor VIII- related antigen in the most neovascularised area of the specimen. The highest level of VEGF mRNA expression was observed in early invasive cervical cancers. Except for stage IVb, the stage of the disease inversely correlated with the level of VEGF mRNA (P
AB - The association between the expression of vascular endothelial growth factor (VEGF) and clinicopathological factors has scarcely been examined in cervical cancer. This study examines the level of VEGF messenger RNA (mRNA) expression in invasive cervical cancer and its association with clinicopathological features including microvessel density. The level of VEGF mRNA was assessed by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) using β-actin as an internal control in 66 patients with stages Ia-IVb invasive cervical cancer. In 42 patients who underwent surgery, the microvessel count was also assessed by immunostaining for factor VIII- related antigen in the most neovascularised area of the specimen. The highest level of VEGF mRNA expression was observed in early invasive cervical cancers. Except for stage IVb, the stage of the disease inversely correlated with the level of VEGF mRNA (P
KW - Angiogenesis
KW - Cervical cancer
KW - Reverse transcription-polymerase chain reaction
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=0004011756&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0004011756&partnerID=8YFLogxK
U2 - 10.1016/S0959-8049(98)00410-9
DO - 10.1016/S0959-8049(98)00410-9
M3 - Article
VL - 35
SP - 485
EP - 489
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 3
ER -